Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy

Iain Stephenson; Roberto Bugarini; Karl G. Nicholson; Audino Podda; John M. Wood; Maria Zambon; Jacqueline M. Katz

doi:10.1086/428948

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy

Iain Stephenson^*, Roberto Bugarini, Karl G. Nicholson, Audino Podda, John M. Wood, Maria Zambon, Jacqueline M. Katz

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

266 Citations (Scopus)

Abstract

Antigenically well-matched vaccines against highly pathogenic avian influenza H5N1 viruses are urgently required. Human serum samples after immunization with MF59 or nonadjuvanted A/duck/Singapore/97 (H5N3) vaccine were tested for antibody to 1997-2004 human H5N1 viruses. Antibody responses to 3 doses of non-adjuvanted vaccine were poor and were higher after MF59-adjuvanted vaccine, with seroconversion rates to A/HongKong/156/97, A/HongKong/213/03, A/Thailand/16/04, and A/Vietnam/1203/04 of 100% (P < .0001), 100% (P < .0001), 71% (P = .0004), and 43% (P = .0128) in 14 subjects, respectively, compared with 27%, 27%, 0%, and 0% in 11 who received nonadjuvanted vaccine. These findings have implications for the rational design of pandemic vaccines against influenza H5.

Original language	English
Pages (from-to)	1210-1215
Number of pages	6
Journal	Journal of Infectious Diseases
Volume	191
Issue number	8
DOIs	https://doi.org/10.1086/428948
Publication status	Published - 15 Apr 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1086/428948

Cite this

Stephenson, I., Bugarini, R., Nicholson, K. G., Podda, A., Wood, J. M., Zambon, M., & Katz, J. M. (2005). Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy. Journal of Infectious Diseases, 191(8), 1210-1215. https://doi.org/10.1086/428948

@article{4530a20b369f4c54b60c3715ed98e23f,

title = "Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy",

abstract = "Antigenically well-matched vaccines against highly pathogenic avian influenza H5N1 viruses are urgently required. Human serum samples after immunization with MF59 or nonadjuvanted A/duck/Singapore/97 (H5N3) vaccine were tested for antibody to 1997-2004 human H5N1 viruses. Antibody responses to 3 doses of non-adjuvanted vaccine were poor and were higher after MF59-adjuvanted vaccine, with seroconversion rates to A/HongKong/156/97, A/HongKong/213/03, A/Thailand/16/04, and A/Vietnam/1203/04 of 100% (P < .0001), 100% (P < .0001), 71% (P = .0004), and 43% (P = .0128) in 14 subjects, respectively, compared with 27%, 27%, 0%, and 0% in 11 who received nonadjuvanted vaccine. These findings have implications for the rational design of pandemic vaccines against influenza H5.",

author = "Iain Stephenson and Roberto Bugarini and Nicholson, {Karl G.} and Audino Podda and Wood, {John M.} and Maria Zambon and Katz, {Jacqueline M.}",

year = "2005",

month = apr,

day = "15",

doi = "10.1086/428948",

language = "English",

volume = "191",

pages = "1210--1215",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "8",

}

Stephenson, I, Bugarini, R, Nicholson, KG, Podda, A, Wood, JM, Zambon, M & Katz, JM 2005, 'Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy', Journal of Infectious Diseases, vol. 191, no. 8, pp. 1210-1215. https://doi.org/10.1086/428948

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy. / Stephenson, Iain; Bugarini, Roberto; Nicholson, Karl G. et al.
In: Journal of Infectious Diseases, Vol. 191, No. 8, 15.04.2005, p. 1210-1215.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine

T2 - A potential priming strategy

AU - Stephenson, Iain

AU - Bugarini, Roberto

AU - Nicholson, Karl G.

AU - Podda, Audino

AU - Wood, John M.

AU - Zambon, Maria

AU - Katz, Jacqueline M.

PY - 2005/4/15

Y1 - 2005/4/15

N2 - Antigenically well-matched vaccines against highly pathogenic avian influenza H5N1 viruses are urgently required. Human serum samples after immunization with MF59 or nonadjuvanted A/duck/Singapore/97 (H5N3) vaccine were tested for antibody to 1997-2004 human H5N1 viruses. Antibody responses to 3 doses of non-adjuvanted vaccine were poor and were higher after MF59-adjuvanted vaccine, with seroconversion rates to A/HongKong/156/97, A/HongKong/213/03, A/Thailand/16/04, and A/Vietnam/1203/04 of 100% (P < .0001), 100% (P < .0001), 71% (P = .0004), and 43% (P = .0128) in 14 subjects, respectively, compared with 27%, 27%, 0%, and 0% in 11 who received nonadjuvanted vaccine. These findings have implications for the rational design of pandemic vaccines against influenza H5.

AB - Antigenically well-matched vaccines against highly pathogenic avian influenza H5N1 viruses are urgently required. Human serum samples after immunization with MF59 or nonadjuvanted A/duck/Singapore/97 (H5N3) vaccine were tested for antibody to 1997-2004 human H5N1 viruses. Antibody responses to 3 doses of non-adjuvanted vaccine were poor and were higher after MF59-adjuvanted vaccine, with seroconversion rates to A/HongKong/156/97, A/HongKong/213/03, A/Thailand/16/04, and A/Vietnam/1203/04 of 100% (P < .0001), 100% (P < .0001), 71% (P = .0004), and 43% (P = .0128) in 14 subjects, respectively, compared with 27%, 27%, 0%, and 0% in 11 who received nonadjuvanted vaccine. These findings have implications for the rational design of pandemic vaccines against influenza H5.

UR - http://www.scopus.com/inward/record.url?scp=17044380507&partnerID=8YFLogxK

U2 - 10.1086/428948

DO - 10.1086/428948

M3 - Article

C2 - 15776364

AN - SCOPUS:17044380507

SN - 0022-1899

VL - 191

SP - 1210

EP - 1215

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 8

ER -

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this